Shire plc Director/PDMR Shareholding
22 February 2017 - 1:33AM
UK Regulatory
TIDMSHP
Director/PDMR Shareholding
February 21, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)
Notification of transactions by person discharging managerial responsibilities
1. Details of the person discharging managerial responsibilities
("PDMR") / person closely associated them ("PCA")
a) Name Perry Sternberg
2. Reason for the notification
a) Position / status Head of US Commercial - PDMR
b) Initial Initial notification
notification /
amendment
3. Details of the issuer, emission allowance participant, auction
platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been conducted
a) Description of Shire plc American Depositary Shares ("ADSs")
the financial
instrument, type
of instrument
Identification ISIN: US82481R1068
code
b) Nature of the Exercise of Stock Appreciation Rights ("SARs") in
transaction respect of 3,558 notional ADSs awarded under the
Shire Portfolio Share Plan and consequent receipt
of ADSs. (Details of related disposals of ADSs are
referenced in the sections below.)
c) Price(s) and Exercise price(s) Volume(s) ADSs received
volume(s)
$119.27 1,202
d) Aggregated N/A (single transaction)
information
e) Date of the February 17, 2017
transaction
f) Place of the N/A
transaction
5. Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been conducted
a) Description of Shire plc American Depositary Shares ("ADSs")
the financial
instrument, type
of instrument
Identification ISIN: US82481R1068
code
b) Nature of the Disposals of ADSs
transaction (Disposals marked with * are in relation to the
exercise of SARs referenced in section 4. above.
Part of the proceeds of these disposals were used
to satisfy personal tax liabilities arising from
the exercise of the SARs.)
c) Price(s) and Price(s) Volume(s)
volume(s)
$180.87* 200
$180.73* 200
$180.73* 200
$180.28 99
$180.29 300
d) Aggregated Weighted average price Volume
information
$180.58 999
e) Date of the February 17, 2017
transaction
f) Place of the NYSE (BQT)
transaction
6. Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been conducted
a) Description of Shire plc American Depositary Shares ("ADSs")
the financial
instrument, type
of instrument
Identification ISIN: US82481R1068
code
b) Nature of the Disposals of ADSs in relation to the exercise of
transaction SARs referenced in section 4. above. Part of the
proceeds of these disposals were used to satisfy
personal tax liabilities arising from the exercise
of the SARs.
c) Price(s) and Price(s) Volume(s)
volume(s)
$180.86 100
$180.85 100
$180.85 185
$180.85 100
$180.71 17
d) Aggregated Weighted average price Volume
information
$180.85 502
e) Date of the February 17, 2017
transaction
f) Place of the NASDAQ
transaction
7. Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been conducted
a) Description of Shire plc American Depositary Shares ("ADSs")
the financial
instrument, type
of instrument
Identification ISIN: US82481R1068
code
b) Nature of the Disposal of ADSs in relation to the exercise of
transaction SARs referenced in section 4. above. Part of the
proceeds of this disposal were used to satisfy
personal tax liabilities arising from the exercise
of the SARs.
c) Price(s) and Price(s) Volume(s)
volume(s)
$180.76 100
d) Aggregated N/A (single transaction)
information
e) Date of the February 17, 2017
transaction
f) Place of the Bats BYX
transaction
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
Investor Relations
Ian Karp ikarp@shire.com +1 781 482 9018
Robert Coates rcoates@shire.com +44 1256 894874
Media
Lisa Adler lisa.adler@shire.com +1 617 588 8607
Debbi Ford debbi.ford@shire.com +1 617 949 9083
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people
with rare diseases. We strive to develop best-in-class products, many of which
are available in more than 100 countries, across core therapeutic areas
including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage
Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary
Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and
deliver breakthrough therapies for the hundreds of millions of people in the
world affected by rare diseases and other high-need conditions, and who lack
effective therapies to live their lives to the fullest.
www.shire.com
END
(END) Dow Jones Newswires
February 21, 2017 09:33 ET (14:33 GMT)
Shire (LSE:SHP)
Historical Stock Chart
From Apr 2024 to May 2024
Shire (LSE:SHP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Shire (London Stock Exchange): 0 recent articles
More Shire News Articles